Evogene (EVGN) investor relations material

AI-driven discovery platform and technology

• Proprietary generative AI engine creates novel, potent small molecules optimized for pharmaceutical and ag-chemical applications, leveraging multi-parameter optimization and chemotype diversity to increase success rates and IP opportunities.

• ChemPass AI™ platform integrates deep learning, virtual screening, and generative models, enabling rapid hit identification, analog search, and simultaneous optimization of multiple molecular parameters.

• Collaborations with Google Cloud have resulted in advanced AI agents and foundation models, achieving up to 90% precision in molecular candidate generation and accelerating design-make-test-analyze cycles.

Business strategy and partnerships

• Strategic co-development partnerships with pharma, ag-chemical, and biotech companies maximize ChemPass AI™ value, sharing expertise and risk while generating new molecular entities.

• Business development targets academia, biotech, and global pharma for joint discovery, shared IP, and milestone-based payments, with timelines ranging from near-term to long-term collaborations.

• Ongoing and new collaborations are expanding both the pharma and ag-chemical pipelines, with a focus on building relationships and evaluating internal projects.

Pharma division: pipeline and collaborations

• AI-driven drug discovery addresses a $1,344B market, with small molecules comprising 58% and AI-based candidates growing at 150% CAGR; discovery market projected to reach ~$190B by 2034.

• Diverse internal and partnered pipeline targets oncology, metabolism, immunology, and neurology, with programs advancing through hit identification, lead optimization, and preclinical stages.

• Notable collaborations include projects for breast cancer and metabolic diseases, demonstrating high hit rates and novel therapeutic modalities using ChemPass AI™.